Zobrazeno 1 - 10
of 24
pro vyhledávání: '"L J, Schaaf"'
Autor:
L. J. Schaaf
Publikováno v:
Transactions of the Royal Society of South Africa. 49:87-102
SUMMARY John Herschel's use of the camera lucida as a drawing aid and the part played by this instrument in Henry Fox Talbot's motivation to invent photography are described. Herschel's seminal contributions to the early progress of photography, his
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::84f27dead523ebcf15c1e30b9ff73a78
https://doi.org/10.1080/00359199409520294
https://doi.org/10.1080/00359199409520294
Autor:
R. G. Petit, J. G. Kuhn, David Rinaldi, Langdon L. Miller, Lisa A. Hammond, Stephanie Hodges, G. I. Rodriguez, Miguel A. Villalona-Calero, S. G. Eckhardt, D. D. Von Hoff, L. J. Schaaf, Mace L. Rothenberg, Paula K. Locker, Gary Elfring, Abhishek Sharma
Publikováno v:
Annals of oncology : official journal of the European Society for Medical Oncology. 12(11)
Summary Objectives This trial was performed to determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetic profile of irinotecan (CPT-11) when administered on a once-every-2-week schedule Patients and methods CPT-11
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a5b218fe11e2b8282f7ea86e52430bd7
https://pubmed.ncbi.nlm.nih.gov/11822765
https://pubmed.ncbi.nlm.nih.gov/11822765
Autor:
H C, Pitot, R M, Goldberg, J M, Reid, J A, Sloan, P A, Skaff, C, Erlichman, J, Rubin, P A, Burch, A A, Adjei, S A, Alberts, L J, Schaaf, G, Elfring, L L, Miller
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 6(6)
A Phase I study was performed to determine the maximum tolerated dose (MTD), toxicities, and pharmacokinetic profile of irinotecan (CPT-11) and its active metabolites when given on a once-every-3-week schedule. Thirty-four patients with advanced refr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dc54ff898c143cde0eaba867dc1758d9
https://pubmed.ncbi.nlm.nih.gov/10873073
https://pubmed.ncbi.nlm.nih.gov/10873073
Autor:
J G, Slatter, L J, Schaaf, J P, Sams, K L, Feenstra, M G, Johnson, P A, Bombardt, K S, Cathcart, M T, Verburg, L K, Pearson, L D, Compton, L L, Miller, D S, Baker, C V, Pesheck, R S, Lord
Publikováno v:
Drug metabolism and disposition: the biological fate of chemicals. 28(4)
This study determined the disposition of irinotecan hydrochloride trihydrate (CPT-11) after i.v. infusion of 125 mg/m(2) (100 microCi) [(14)C]CPT-11 in eight patients with solid tumors. Mean +/- S.D. recovery of radioactivity in urine and feces was 9
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a052ff69246a2104d461df4a37672029
https://pubmed.ncbi.nlm.nih.gov/10725311
https://pubmed.ncbi.nlm.nih.gov/10725311
Autor:
M L, Rothenberg, J G, Kuhn, L J, Schaaf, R L, Drengler, S G, Eckhardt, M A, Villalona-Calero, L, Hammond, L L, Miller, R G, Petit, E K, Rowinsky, D D, Von Hoff
Publikováno v:
Oncology (Williston Park, N.Y.). 12(8 Suppl 6)
Most of the clinical experience with irinotecan (CPT-11 [Camptosar]) has been with either a weekly or an every-3-week schedule. Recent phase I trials have explored new routes and schedules of administration. One approach attempts to maximize dose fre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d28c38ae6b9960c9a805473f11bb6b05
https://pubmed.ncbi.nlm.nih.gov/9726095
https://pubmed.ncbi.nlm.nih.gov/9726095